Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xenetic Biosciences, Inc. (XBIO)
USD2.90
-0.10 (-3.33%)
US NASDAQ Healthcare Biotechnology
Address
40 Speen Street 1701
Framingham, MA, US
Framingham, MA, US
CEO
James F. Parslow
Website
xeneticbio.com
IPO
2016-06-30
CIK 1534525 ISIN US9840156023
Also trades on
NASDAQ Capital Market · XBIO (USD)
NASDAQ Capital Market · XBIOW (USD)
Description
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.90
-0.10 (-3.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
16.5K
Beta
2.20
Float Shares
1.43M
Free Float %
84.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.68% | -3.98% | -1.16% | +26.55% | +14.57% | +39.38% | -2.43% | -8.35% | -82.72% | -99.51% | -99.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
2.90
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-31.81
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+19.0% ★ Q1'26: +36.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+38.5% ★ Q1'26: +66.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-84.2% Q1'26: -66.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-95.2% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.4% Q1'26: +48.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
436.9K
est: 412.5K (+5.9%)
|
1.16M
est: 800.0K (+45.1%)
|
1.71M
est: 1.70M (+0.4%)
|
2.54M
est: 2.50M (+1.6%)
|
2.50M
est: 2.50M (+0.0%)
|
2.98M
est: 2.50M (+19.1%)
|
3.00M
3.00M – 3.00M
+20.0% YoY
|
2.50M
2.50M – 2.50M
-16.7% YoY
|
9.70M
9.70M – 9.70M
+288.0% YoY
|
| EBITDA |
-4.67M
est: -412.5K (-1,031.1%)
|
-5.71M
est: -800.0K (-613.9%)
|
-6.69M
est: -1.70M (-293.6%)
|
-4.52M
est: -2.50M (-80.6%)
|
-4.05M
est: -2.48M (-63.6%)
|
-2.83M
est: -2.48M (-14.5%)
|
-2.97M
-2.97M – -2.97M
-20.0% YoY
|
-2.48M
-2.48M – -2.48M
+16.7% YoY
|
-9.61M
-9.61M – -9.61M
-288.0% YoY
|
| EBIT |
-4.69M
est: -412.5K (-1,038.1%)
|
-5.75M
est: -800.0K (-618.3%)
|
-6.72M
est: -1.70M (-295.2%)
|
-4.52M
est: -2.50M (-80.6%)
|
-4.20M
est: -2.48M (-69.8%)
|
-2.83M
est: -2.48M (-14.5%)
|
-2.97M
-2.97M – -2.97M
-20.0% YoY
|
-2.48M
-2.48M – -2.48M
+16.7% YoY
|
-9.61M
-9.61M – -9.61M
-288.0% YoY
|
| Net Income |
-10.89M
est: -24.66M (+55.8%)
|
-5.65M
est: -8.48M (+33.4%)
|
-6.55M
est: -7.09M (+7.6%)
|
-4.13M
est: -1.06M (-288.8%)
|
-3.96M
est: -4.37M (+9.4%)
|
-2.68M
est: -3.47M (+22.8%)
|
-5.65M
-5.65M – -5.65M
-62.7% YoY
|
-578.5K
-578.5K – -578.5K
+89.8% YoY
|
-391.4K
-391.4K – -391.4K
+32.4% YoY
|
| SGA |
3.40M
est: 1.31M (+158.9%)
|
3.74M
est: 2.55M (+47.0%)
|
3.65M
est: 5.41M (-32.5%)
|
3.56M
est: 7.96M (-55.3%)
|
3.42M
est: 4.53M (-24.6%)
|
2.75M
est: 4.53M (-39.4%)
|
5.43M
5.43M – 5.43M
+20.0% YoY
|
4.53M
4.53M – 4.53M
-16.7% YoY
|
17.57M
17.57M – 17.57M
+288.0% YoY
|
| EPS |
-17.04
est: -16.00 (-6.5%)
|
-5.39
est: -5.50 (+2.0%)
|
-4.49
est: -4.60 (+2.4%)
|
-2.71
est: -0.69 (-292.8%)
|
-2.57
est: -2.57 (+0.0%)
|
-1.58
est: -2.04 (+22.5%)
|
-3.32
-3.32 – -3.32
-62.7% YoY
|
-0.34
-0.34 – -0.34
+89.8% YoY
|
-0.23
-0.23 – -0.23
+32.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.28M
OE per share TTM
-1.43
Owner's Yield
-31.76%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
1
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Empery Asset Management, LP | 1.55M | 9.99% | — | 1.55M | — | — | PN | Delaware | 2019-03-11 | ↗ |
| 2 | Martin D. Hoe | 1.55M | 9.99% | — | 1.55M | — | — | IN | United States | 2019-03-11 | ↗ |
| 3 | Ryan M. Lane | 1.55M | 9.99% | — | 1.55M | — | — | IN | United States | 2019-03-11 | ↗ |
| 4 | Empery Tax Efficient II, LP | 1.27M | 9.99% | — | 1.27M | — | — | PN | Delaware | 2019-03-11 | ↗ |
| 5 | 13G | 260.0K | 9.80% | — | 260.0K | — | 260.0K | IN | Ontario, Canada | 2019-07-29 | ↗ |
| 6 | CVI Investments, Inc. | 235.0K | 8.90% | — | 235.0K | — | 235.0K | CO | Cayman Islands | 2019-08-07 | ↗ |
| 7 | Heights Capital Management, Inc. | 235.0K | 8.90% | — | 235.0K | — | 235.0K | CO | Delaware | 2019-08-07 | ↗ |
| 8 | Dmitry Genkin | 198.9K | 13.00% | 51.4K | 147.5K | 51.4K | 147.5K | IN | Israel | 2023-09-18 | ↗ |
| 9 | CLS Therapeutics Ltd. | 147.5K | 9.60% | 147.5K | — | 147.5K | — | CO | UK | 2023-09-18 | ↗ |
| 10 | Georgy Tets | 147.5K | 9.60% | — | 147.5K | — | 147.5K | IN | States | 2023-09-18 | ↗ |
| 11 | Victor Tets | 147.5K | 9.60% | — | 147.5K | — | 147.5K | IN | States | 2023-09-18 | ↗ |
| 12 | M. Scott Maguire | 6.0K | 0.40% | 3.8K | 2.2K | 3.8K | 2.2K | IN | Kingdom | 2023-09-18 | ↗ |
| 13 | M. Scot Maguire | 2.2K | 0.01% | — | 2.2K | — | 2.2K | IN | Kingdom | 2023-06-15 | ↗ |
| 14 | 13G/A | — | 0.00% | — | — | — | — | HC, IN | — | 2020-02-14 | ↗ |
| 15 | Altium Capital Management, LP | — | 0.00% | — | — | — | — | IA | Delaware, United States of America | 2020-02-13 | ↗ |
| 16 | Altium Growth Fund, LP | — | 0.00% | — | — | — | — | PN | Delaware, United States of America | 2020-02-13 | ↗ |
| 17 | Altium Growth GP, LLC | — | 0.00% | — | — | — | — | PN | Delaware, United States of America | 2020-02-13 | ↗ |
| 18 | Daniel B. Asher | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2020-12-21 | ↗ |
| 19 | Intracoastal Capital LLC | — | 0.00% | — | — | — | — | OO | United States of America | 2020-12-21 | ↗ |
| 20 | Mitchell P. Kopin | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2020-12-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 38.7K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | PARSLOW JAMES F | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2025-12-31 | VINOGRADOV ALEXEY ANDREEVICH | Director | A-Award | A | Stock Options | 2,500 | 2.17 | 5.4K | 2,500 | D | ↗ |
| 2025-12-31 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 2,500 | 2.17 | 5.4K | 2,500 | D | ↗ |
| 2025-12-31 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 2,500 | 2.17 | 5.4K | 2,500 | D | ↗ |
| 2025-12-31 | Borisenko Grigory G. | Director | A-Award | A | Stock Options | 2,500 | 2.17 | 5.4K | 2,500 | D | ↗ |
| 2024-12-11 | VINOGRADOV ALEXEY ANDREEVICH | Director | A-Award | A | Stock Options | 2,500 | 4.24 | 10.6K | 2,500 | D | ↗ |
| 2024-12-11 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 2,500 | 4.24 | 10.6K | 2,500 | D | ↗ |
| 2024-12-11 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 2,500 | 4.24 | 10.6K | 2,500 | D | ↗ |
| 2024-12-11 | Borisenko Grigory G. | Director | A-Award | A | Stock Options | 2,500 | 4.24 | 10.6K | 2,500 | D | ↗ |
| 2024-06-18 | PARSLOW JAMES F | Officer | A-Award | A | Stock Options | 20,000 | 3.99 | 79.8K | 20,000 | — | ↗ |
| 2023-12-11 | PARSLOW JAMES F | Officer | A-Award | A | Stock Options | 10,000 | 3.88 | 38.8K | 10,000 | — | ↗ |
| 2023-12-11 | Lockshin Curtis | Officer | A-Award | A | Stock Options | 10,000 | 3.88 | 38.8K | 10,000 | — | ↗ |
| 2023-12-11 | EISENBERG JEFFREY F | Director / Officer | A-Award | A | Stock Options | 20,000 | 3.88 | 77.6K | 20,000 | — | ↗ |
| 2023-12-06 | VINOGRADOV ALEXEY ANDREEVICH | Director | A-Award | A | Stock Options | 2,500 | 4.29 | 10.7K | 2,500 | — | ↗ |
| 2023-12-06 | Mizrahy Moshe | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-06 | Logal Adam | Director | A-Award | A | Stock Options | 2,500 | 4.29 | 10.7K | 2,500 | — | ↗ |
| 2023-12-06 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 2,500 | 4.29 | 10.7K | 2,500 | — | ↗ |
| 2023-12-06 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 2,500 | 4.29 | 10.7K | 2,500 | — | ↗ |
| 2023-12-06 | Callaway James Eric | Director | A-Award | A | Stock Options | 2,500 | 4.29 | 10.7K | 2,500 | — | ↗ |
| 2023-12-06 | Borisenko Grigory G. | Director | A-Award | A | Stock Options | 2,500 | 4.29 | 10.7K | 2,500 | — | ↗ |
| 2022-12-07 | VINOGRADOV ALEXEY ANDREEVICH | Director | A-Award | A | Stock Options | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-12-07 | Logal Adam | Director | A-Award | A | Stock Options | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-12-07 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-12-07 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-12-07 | Callaway James Eric | Director | A-Award | A | Stock Options | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-12-07 | Borisenko Grigory G. | Director | A-Award | A | Stock Options | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-03-24 | PARSLOW JAMES F | Officer | A-Award | A | Stock Options | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-03-24 | Lockshin Curtis | Officer | A-Award | A | Stock Options | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-03-24 | EISENBERG JEFFREY F | Director / Officer | A-Award | A | Stock Options | 100,000 | 1.12 | 112.0K | 100,000 | — | ↗ |
| 2021-12-07 | VINOGRADOV ALEXEY ANDREEVICH | Director | A-Award | A | Stock Options | 25,000 | 1.44 | 36.0K | 25,000 | — | ↗ |
| 2021-12-07 | Logal Adam | Director | A-Award | A | Stock Options | 25,000 | 1.44 | 36.0K | 25,000 | — | ↗ |
| 2021-12-07 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 25,000 | 1.44 | 36.0K | 25,000 | — | ↗ |
| 2021-12-07 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 25,000 | 1.44 | 36.0K | 25,000 | — | ↗ |
| 2021-12-07 | Callaway James Eric | Director | A-Award | A | Stock Options | 25,000 | 1.44 | 36.0K | 25,000 | — | ↗ |
| 2021-03-18 | PARSLOW JAMES F | Officer | A-Award | A | Stock Options | 50,000 | 2.60 | 130.0K | 50,000 | — | ↗ |
| 2021-03-18 | Lockshin Curtis | Officer | A-Award | A | Stock Options | 50,000 | 2.60 | 130.0K | 50,000 | — | ↗ |
| 2021-03-18 | EISENBERG JEFFREY F | Director / Officer | A-Award | A | Stock Options | 100,000 | 2.60 | 260.0K | 100,000 | — | ↗ |
| 2020-12-04 | VINOGRADOV ALEXEY ANDREEVICH | Director | A-Award | A | Stock Options | 25,000 | 1.10 | 27.5K | 25,000 | — | ↗ |
| 2020-12-04 | Logal Adam | Director | A-Award | A | Stock Options | 25,000 | 1.10 | 27.5K | 25,000 | — | ↗ |
| 2020-12-04 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 25,000 | 1.10 | 27.5K | 25,000 | — | ↗ |
| 2020-12-04 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 25,000 | 1.10 | 27.5K | 25,000 | — | ↗ |
| 2020-12-04 | Callaway James Eric | Director | A-Award | A | Stock Options | 25,000 | 1.10 | 27.5K | 25,000 | — | ↗ |
| 2020-01-01 | Lockshin Curtis | Officer | — | D | Stock Option | 58,333 | 0.00 | — | 0 | — | ↗ |
| 2019-12-04 | PARSLOW JAMES F | Officer | A-Award | A | Stock Options | 80,000 | 1.31 | 104.8K | 80,000 | — | ↗ |
| 2019-12-04 | Logal Adam | Director | A-Award | A | Stock Options | 25,000 | 1.31 | 32.8K | 25,000 | — | ↗ |
| 2019-12-04 | Lockshin Curtis | Officer | A-Award | A | Stock Options | 90,000 | 1.31 | 117.9K | 90,000 | — | ↗ |
| 2019-12-04 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 25,000 | 1.31 | 32.8K | 25,000 | — | ↗ |
| 2019-12-04 | EISENBERG JEFFREY F | Director / Officer | A-Award | A | Stock Options | 230,000 | 1.31 | 301.3K | 230,000 | — | ↗ |
| 2019-12-04 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 25,000 | 1.31 | 32.8K | 25,000 | — | ↗ |
| 2019-12-04 | Callaway James Eric | Director | A-Award | A | Stock Options | 25,000 | 1.31 | 32.8K | 25,000 | — | ↗ |
| 2019-09-26 | VINOGRADOV ALEXEY ANDREEVICH | Director | A-Award | A | Stock Options | 25,000 | 1.40 | 34.9K | 25,000 | — | ↗ |
| 2019-09-26 | Borisenko Grigory G. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-07-19 | VINOGRADOV ALEXEY ANDREEVICH | Director | — | D | Common Stock | 0 | 0.00 | — | 186,781 | — | ↗ |
| 2019-07-19 | Genkin Dmitry | Director | A-Award | A | Common Stock | 93,390 | 0.00 | — | 93,603 | — | ↗ |
| 2018-11-28 | Logal Adam | Director | A-Award | A | Stock Options | 25,000 | 3.05 | 76.3K | 25,000 | — | ↗ |
| 2018-11-28 | Kornberg Roger D. | Director | A-Award | A | Stock Options | 25,000 | 3.05 | 76.3K | 25,000 | — | ↗ |
| 2018-11-28 | Dastoor Firdaus J. | Director | A-Award | A | Stock Options | 25,000 | 3.05 | 76.3K | 25,000 | — | ↗ |
| 2018-11-28 | Callaway James Eric | Director | A-Award | A | Stock Options | 25,000 | 3.05 | 76.3K | 25,000 | — | ↗ |
| 2018-03-14 | Genkin Dmitry | Director | J-Other | D | Common Stock | 29,452 | 0.00 | — | 2,549 | — | ↗ |
| 2017-11-15 | Kornberg Roger D. | Director | A-Award | A | Stock Option | 25,000 | 2.18 | 54.5K | 25,000 | — | ↗ |
| 2017-11-15 | Dastoor Firdaus J. | Director | A-Award | A | Stock Option | 25,000 | 2.18 | 54.5K | 25,000 | — | ↗ |
| 2017-10-26 | EISENBERG JEFFREY F | Director / Officer | A-Award | A | Stock Options | 250,000 | 2.11 | 527.5K | 250,000 | — | ↗ |
| 2017-10-11 | Logal Adam | Director | A-Award | A | Stock Option | 6,250 | 2.95 | 18.4K | 6,250 | — | ↗ |
| 2017-10-11 | Callaway James Eric | Director | A-Award | A | Stock Option | 6,250 | 2.95 | 18.4K | 18,750 | — | ↗ |
| 2017-08-14 | Logal Adam | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-14 | Genkin Dmitry | Director | — | D | Common Stock | 0 | 0.00 | — | 32,000 | — | ↗ |
| 2017-08-14 | Callaway James Eric | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-09 | DEPTULA-HICKS DARLENE M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-09 | Benz Edward J. JR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-04-03 | PARSLOW JAMES F | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 175,000 | 4.57 | 799.8K | 175,000 | — | ↗ |
| 2016-12-20 | Maguire Michael Scott | Director / Officer | A-Award | A | Stock Option | 83,333 | 3.50 | 291.7K | 250,000 | — | ↗ |
| 2016-12-20 | Kornberg Roger D. | Director | A-Award | A | Stock Option | 3,030 | 10.23 | 31.0K | 3,030 | — | ↗ |
| 2016-12-20 | DEPTULA-HICKS DARLENE M | Director | A-Award | A | Stock Option | 10,000 | 3.50 | 35.0K | 40,000 | — | ↗ |
| 2016-12-20 | Benz Edward J. JR | Director | A-Award | A | Stock Option | 6,250 | 3.49 | 21.8K | 25,000 | — | ↗ |
| 2016-12-02 | EISENBERG JEFFREY F | Director / Officer | A-Award | A | Stock Options | 75,100 | 3.40 | 255.3K | 230,000 | — | ↗ |
| 2016-11-21 | Benz Edward J. JR | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-11-07 | PJSC Pharmsynthez | 10% Owner | — | D | Class B Warrants | 1,454,545 | 4.00 | 5.82M | 0 | — | ↗ |
| 2016-11-01 | Maguire Michael Scott | Director | — | D | Common Stock | 0 | 0.00 | — | 73,953 | — | ↗ |
| 2016-11-01 | Kornberg Roger D. | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-11-01 | Knyazev Roman | Director | — | D | Stock Options | 37,879 | 4.59 | 173.9K | 0 | — | ↗ |
| 2016-11-01 | EISENBERG JEFFREY F | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-11-01 | Dastoor Firdaus J. | Director | — | D | Stock Options | 45,455 | 4.59 | 208.6K | 0 | — | ↗ |
| 2016-11-01 | DEPTULA-HICKS DARLENE M | Director | — | D | Stock Options | 30,304 | 4.59 | 139.1K | 0 | — | ↗ |
| 2016-09-09 | PJSC Pharmsynthez | 10% Owner | — | D | Warrants | 32,526 | 4.95 | 161.0K | 0 | — | ↗ |
| 2016-09-06 | Maguire Michael Scott | Director | — | D | Stock Options | 70,707 | 4.59 | 324.5K | 0 | — | ↗ |
| 2016-09-06 | Knyazev Roman | Director | — | D | Stock Options | 12,626 | 4.59 | 58.0K | 0 | — | ↗ |
| 2016-09-06 | Dastoor Firdaus J. | Director | — | D | Stock Options | 15,151 | 4.59 | 69.5K | 0 | — | ↗ |
| 2016-09-06 | DEPTULA-HICKS DARLENE M | Director | — | D | Stock Options | 10,101 | 4.59 | 46.4K | 0 | — | ↗ |
| 2016-07-01 | PJSC Pharmsynthez | 10% Owner | — | D | Warrants | 50,506 | 0.00 | — | 0 | — | ↗ |
| 2016-07-01 | Maguire Michael Scott | Director | — | D | Warrants | 37,369 | 6.60 | 246.6K | 0 | — | ↗ |
| 2016-04-27 | Genkin Dmitry | Director | — | D | Stock Options | 30,304 | 13.86 | 420.0K | 0 | — | ↗ |
| 2015-09-06 | Genkin Dmitry | Director | — | D | Stock Options | 37,879 | 4.59 | 173.9K | 0 | — | ↗ |
| 2014-12-31 | PJSC Pharmsynthez | 10% Owner | — | I | Warrants | 204,394 | 25.41 | 5.19M | 0 | — | ↗ |
| 2014-12-31 | LLC Synbio | 10% Owner | — | D | Warrants | 204,394 | 25.41 | 5.19M | 0 | — | ↗ |
| 2014-12-31 | Dastoor Firdaus J. | Director | — | D | Warrants | 48,485 | 7.92 | 384.0K | 0 | — | ↗ |
| 2014-01-23 | PJSC Pharmsynthez | 10% Owner | — | I | Series A Preferred Stock | 0 | 0.00 | — | 970,000 | — | ↗ |
| 2014-01-23 | LLC Synbio | 10% Owner | — | D | Series A Preferred Stock | 0 | 0.00 | — | 970,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.42M
Shares Outstanding
1.70M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Jeffrey F. Eisenberg, Chief Executive Officer | 367.5K | — | — | 234.1K | 119.4K | 29.2K | 750.2K | 31.20% | ↗ |
| 2 | 2021 | James Parslow, Chief Financial Officer | 299.3K | — | — | 117.0K | 68.1K | 36.5K | 520.8K | 22.47% | ↗ |
| 3 | 2021 | Dr. Curtis Lockshin, Chief Scientific Officer | 299.3K | — | — | 117.0K | 68.1K | 24.0K | 508.3K | 23.02% | ↗ |
| 4 | 2020 | Jeffrey F. Eisenberg, Chief Executive Officer | 350.0K | — | — | — | 68.3K | 28.1K | 446.4K | 0.00% | ↗ |
| 5 | 2020 | James Parslow, Chief Financial Officer | 285.0K | — | — | — | 38.9K | 35.5K | 359.4K | 0.00% | ↗ |
| 6 | 2020 | Dr. Curtis Lockshin, Chief Scientific Officer | 285.0K | — | — | — | 38.9K | 23.3K | 347.2K | 0.00% | ↗ |
| 7 | 2019 | Jeffrey F. Eisenberg, Chief Executive Officer | 300.0K | — | — | 287.1K | — | 15.6K | 602.7K | 47.64% | ↗ |
| 8 | 2019 | James Parslow, Chief Financial Officer | 265.0K | — | — | 99.9K | — | 23.0K | 387.8K | 25.75% | ↗ |
| 9 | 2019 | Dr. Curtis Lockshin, Chief Scientific Officer | 250.0K | — | — | 112.3K | — | 21.5K | 383.8K | 29.27% | ↗ |
| 10 | 2018 | Jeffrey F. Eisenberg, Chief Executive Officer | 300.0K | — | — | — | — | 18.3K | 318.3K | 0.00% | ↗ |
| 11 | 2018 | James Parslow, Chief Financial Officer | 265.0K | — | — | — | — | 22.6K | 287.6K | 0.00% | ↗ |
| 12 | 2018 | Dr. Curtis Lockshin, Chief Scientific Officer | 250.0K | — | — | — | — | 9.6K | 259.6K | 0.00% | ↗ |
| 13 | 2017 | James Parslow Chief Financial Officer | 198.8K | — | — | 667.2K | — | 24.8K | 890.8K | 74.90% | ↗ |
| 14 | 2017 | James Parslow, Chief Financial Officer | 198.8K | — | — | 667.2K | — | 24.8K | 890.8K | 74.90% | ↗ |
| 15 | 2017 | Dr. Curtis Lockshin, Chief Scientific Officer | 250.0K | — | — | 625.3K | — | 2.5K | 877.8K | 71.23% | ↗ |
| 16 | 2017 | Dr. Curtis Lockshin, Chief Scientific Officer | 250.0K | — | — | 625.3K | — | 2.5K | 877.8K | 71.23% | ↗ |
| 17 | 2017 | Jeffrey F. Eisenberg, Chief Executive Officer | 300.0K | — | 105.7K | 375.4K | — | 34.4K | 815.5K | 59.00% | ↗ |
| 18 | 2017 | Jeffrey F. Eisenberg, Chief Executive Officer | 300.0K | — | 105.7K | 375.4K | — | 34.4K | 815.5K | 59.00% | ↗ |
| 19 | 2017 | M. Scott Maguire, Former Chief Executive Officer | 470.6K | — | — | — | — | 164.9K | 635.5K | 0.00% | ↗ |
| 20 | 2016 | M. Scott Maguire, Chief Executive Officer | 456.1K | — | — | 727.2K | 206.6K | 78.6K | 1.47M | 49.52% | ↗ |
| 21 | 2016 | M. Scott Maguire, Former Chief Executive Officer | 456.1K | — | — | 727.2K | 206.6K | 78.6K | 1.47M | 49.52% | ↗ |
| 22 | 2016 | Jeffrey F. Eisenberg, Chief Executive Officer | 41.8K | — | — | 649.0K | — | 3.0K | 693.8K | 93.54% | ↗ |
| 23 | 2016 | Jeffrey F. Eisenberg, Chief | 41.8K | — | — | 649.0K | — | 3.0K | 693.8K | 93.54% | ↗ |
| 24 | 2015 | M. Scott Maguire, Chief Executive Officer | 505.7K | — | — | 1.98M | — | 60.7K | 2.55M | 77.80% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James F. Parslow | Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer & Corporate Secretary | 536.0K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XBIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
